Literature DB >> 15527104

Parent phenotype and age dependence, on rat glioma tumor rejection.

Alicia Gonzalez-Martin1, Daniel Muñoz-Espin, Andrés M Alonso, Marta Izquierdo.   

Abstract

BACKGROUND: The brain, despite the blood-brain barrier, does not escape to the highly variable host rejection response mediated by a very strong and complex immune reaction when rat glioma cells are transplanted into the adult animal.
METHODS: Crosses were performed among parents that are able or enable to reject a well-known brain tumor cell line (C6). Newborn animals were also challenged with rat glioma cells both in the brain and the side flanks.
RESULTS: The percentage of susceptibility or resistance to develop a lethal glioma can be estimated knowing the parental phenotypes. When both parents had rejected an induced tumor, 63% of the progeny will also reject it. Similarly, if both parents died as a consequence of the tumor, 70% of the progeny would also be unable to reject the challenge of glioma C6 cells. Newborn animals do not have a mature immune system and they tolerate transplanted cells much better than adults. We found no rejection to glioma C6, at both brain and side flank sites, in 1-day-old neonatal Wistar rats. Tumors were beginning to be eliminated if the cells are inoculated at day 3 from birth on the flanks, and at 1 week from birth on the brain.
CONCLUSIONS: There is a genetic component conferring susceptibility or resistance to the lethal effect of tumor development and progression depending on the parental phenotype of the adult rats. Neonatal rats represent a much more reliable model than adults to study experimental therapies against gliomas.

Entities:  

Mesh:

Year:  2004        PMID: 15527104     DOI: 10.1023/b:neon.0000040838.40115.f5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  8 in total

Review 1.  Gene polymorphisms and transplantation.

Authors:  E Akalin; B Murphy
Journal:  Curr Opin Immunol       Date:  2001-10       Impact factor: 7.486

Review 2.  Genetics of the immune response: identifying immune variation within the MHC and throughout the genome.

Authors:  Daniel E Geraghty; Riza Daza; Luke M Williams; Quyen Vu; Akiko Ishitani
Journal:  Immunol Rev       Date:  2002-12       Impact factor: 12.988

Review 3.  Genomic and funtional aspects of the rat MHC, the RT1 complex.

Authors:  R Dressel; L Walter; E Günther
Journal:  Immunol Rev       Date:  2001-12       Impact factor: 12.988

4.  Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model.

Authors:  A S Beutler; M S Banck; D Wedekind; H J Hedrich
Journal:  Hum Gene Ther       Date:  1999-01-01       Impact factor: 5.695

5.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

Authors:  D Barba; J Hardin; M Sadelain; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Differentiated rat glial cell strain in tissue culture.

Authors:  P Benda; J Lightbody; G Sato; L Levine; W Sweet
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

7.  Long-term rat survival after malignant brain tumor regression by retroviral gene therapy.

Authors:  M Izquierdo; M Cortés; P de Felipe; V Martín; J Díez-Guerra; A Talavera; A Perez-Higueras
Journal:  Gene Ther       Date:  1995-01       Impact factor: 5.250

8.  Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

Authors:  J Trojan; T R Johnson; S D Rudin; J Ilan; M L Tykocinski; J Ilan
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

  8 in total
  3 in total

1.  Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Authors:  Annelise Letourneur; Simon Roussel; Myriam Bernaudin; Fabien Fillesoye; Jérôme Toutain; Eric T MacKenzie; Edwige Petit; Omar Touzani; Samuel Valable
Journal:  Hypertens Res       Date:  2015-06-18       Impact factor: 3.872

2.  A Truncated form of CD200 (CD200S) Expressed on Glioma Cells Prolonged Survival in a Rat Glioma Model by Induction of a Dendritic Cell-Like Phenotype in Tumor-Associated Macrophages.

Authors:  Kana Kobayashi; Hajime Yano; Akihiro Umakoshi; Shirabe Matsumoto; Ayano Mise; Yu Funahashi; Yoshitomo Ueno; Yoshiaki Kamei; Yasutsugu Takada; Yoshiaki Kumon; Takanori Ohnishi; Junya Tanaka
Journal:  Neoplasia       Date:  2016-04       Impact factor: 5.715

3.  Proton minibeam radiation therapy widens the therapeutic index for high-grade gliomas.

Authors:  Yolanda Prezado; Gregory Jouvion; Annalisa Patriarca; Catherine Nauraye; Consuelo Guardiola; Marjorie Juchaux; Charlotte Lamirault; Dalila Labiod; Laurene Jourdain; Catherine Sebrie; Remi Dendale; Wilfredo Gonzalez; Frederic Pouzoulet
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.